inspiring canadians to live better.

healthing leaf

inspiring canadians to live better.

healthing leaf
mosquito-borne diseases affect up to 700 million people each year. learn more
powered by: valneva canada inc.
home / 世界杯决赛2022

antiviral pill paxlovid reduces risk of long covid: study

paxlovid also reduced the risk of hospitalization or death following acute covid-19.

by postmedia news

nov 13 2022
read time 1 minute read
join the conversation

antiviral pill paxlovid can do more than reduce the risk of hospitalization and death from covid-19, according to a new study

paxlovid can also reduce the risk of long covid, according to research conducted by the u.s. department of veterans affairs, cnn reported .

posted online last week, the study looked at electronic records of more than 56,000 veterans with covid-19, including more than 9,000 who were treated with paxlovid within the first five days of their infection, said the report.
the data showed those treated with paxlovid had a 26% reduced risk of developing long covid conditions such as heart disease, blood disorders, fatigue, liver disease, kidney disease, muscle pain and more.
paxlovid also reduced the risk of hospitalization or death following acute covid-19.
the research found that there wasn’t a statistically significant link between taking paxlovid and risk of two long covid conditions: coughs and new diabetes diagnoses, according to cnn.
patients included in the study had an average age of 65 and were diagnosed with covid-19 between march 1 and june 30.
they all had at least one risk factor for progression to severe covid, such as older age, diabetes or being a smoker. paxlovid reduced the risk of long covid in people who were unvaccinated, vaccinated and boosted, and in people experiencing their first covid infection or a reinfection, the study said.

recommended video

powered by
canadian centre for caregiving excellence

advertisement

“paxlovid reduces the risk of severe covid-19 in the acute phase, and now, we have evidence that it can help reduce the risk of long covid,” dr. ziyad al-aly, chief of research and development at the va st. louis health care system and leader of the study, said in a news release. “this treatment could be an important asset to address the serious issue of long covid.”
a limitation of the study was that most of the people involved were white and male.
powered by
obesity matters
postmedia news
postmedia news
read more about the author

comments

postmedia is committed to maintaining a lively but civil forum for discussion and encourage all readers to share their views on our articles. comments may take up to an hour for moderation before appearing on the site. we ask you to keep your comments relevant and respectful. we have enabled email notifications—you will now receive an email if you receive a reply to your comment, there is an update to a comment thread you follow or if a user you follow comments. visit our community guidelines for more information and details on how to adjust your email settings.